While the announcement of favorable preliminary results has generated excitement for a possible coronavirus vaccine, some in the scientific establishment have begun to question Moderna's choice to publicize results by press release with no supporting data.
ABC News looks at how America reacted to the rising coronavirus death toll and unprecedented unemployment numbers in April.Moderna Inc., a nearly 10-year-old Massachusetts-based biotech company, is suddenly the talk of the scientific community after they announced this week"positive" indications from their early work on a potential vaccine against the novel coronavirus.The company has been embraced by a Trump administration desperate for good news in the fight against COVID-19.
People come and go outside Moderna headquarters in Cambridge, Mass., May 8, 2020. Moderna was given FDA approval to continue to phase 2 of Coronavirus vaccine trials with 600 participants. In response to questions from ABC News, Moderna's Chief Executive Officer Stéphane Bancel issued a brief statement.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Scientists Raise Questions About Moderna Vaccine In Market-Shaking ReportVaccine experts have expressed skepticism about the Covid-19 vaccine trial results announced by Moderna—saying that the company has yet to release significant data to support its claim that its drug has successfully produced antibodies in human trials
Weiterlesen »
Moderna would never release coronavirus vaccine data different from 'reality,' chairman saysThe company put out the extent of data it had available, Moderna Chairman Noubar Afeyan tells CNBC.
Weiterlesen »
Lonza CEO says on pace to make Moderna trial vaccine in June/July: CNBCContract drug manufacturer Lonza still expects to supply drugmaker Moderna with active ingredients for its experimental COVID-19 vaccine by June or July to support laboratory trials, the Swiss company's interim CEO, Albert Baehny, told CNBC on Wednesday.
Weiterlesen »
Morgan Stanley now sees Moderna shares spiking 26% from current levels, cites 65% chance of success for virus vaccine (MRNA) | Markets InsiderMorgan Stanley raised its Moderna price target to $90 from $37, citing 'initial promising Covid-19 vaccine data,' according to a Wednesday note....
Weiterlesen »
Coronavirus live updates: Universal Orlando sets June target date for reopening, more states opening indoor dining at restaurants“There’s a long road ahead, but, you know, the early data was reassuring,” Dr. Scott Gottlieb says, after Moderna reported positive data on its coronavirus vaccine trial earlier this week.
Weiterlesen »
Johnson & Johnson Is Stopping Talc Baby Powder Sales in North AmericaRead about a recent press release from Johnson & Johnson, which stated that they would be stopping the sales for their highly contested product, talc-based baby powder, in North America.
Weiterlesen »